From the Division of Endocrinology and Molecular Medicine, Department of Medicine, University of Kentucky, Lexington (K.A.).
Departments of Medicine (Cardiology) and Cell Biology, and the Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York (A.W.).
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1343-1350. doi: 10.1161/ATVBAHA.119.312371. Epub 2019 May 23.
Osteoporosis and cardiovascular diseases are major public health issues. Bone and cardiovascular remodeling share multiple biological markers and pathways. Medical intervention, such as using romosozumab, an antisclerostin antibody, improves the clinical outcome of osteoporosis. However, blocking sclerostin leads to Wnt (wingless/integrated) activation and participation in the cardiovascular remodeling process, which could potentially lead to adverse events. Based on the opposing roles of bisphosphonates and the Wnt pathway on endothelial dysfunction, lipid accumulation and calcification of the vessel walls, the combination of romosozumab and bisphosphonates could be a new therapeutic approach to reducing the risks of adverse cardiovascular events in romosozumab receivers. Visual Overview- An online visual overview is available for this article.
骨质疏松症和心血管疾病是主要的公共卫生问题。骨骼和心血管重塑共享多种生物学标志物和途径。医学干预，如使用抗硬骨素抗体罗莫佐单抗，可以改善骨质疏松症的临床结局。然而，阻断硬骨素会导致 Wnt（无翅型/整合素）激活并参与心血管重塑过程，这可能导致不良事件。基于双磷酸盐和 Wnt 通路对血管内皮功能障碍、脂质积累和血管壁钙化的相反作用，罗莫佐单抗和双磷酸盐的联合应用可能是降低罗莫佐单抗使用者不良心血管事件风险的一种新的治疗方法。 可视化概述-本文提供了在线可视化概述。
